What question did this study set out to answer?

To review clinical characteristics and evaluate outcomes of intensive immunochemotherapy followed by stem cell transplantation in patients with primary central nervous system lymphoma.

June 16, 2017Hematology/Oncology and Stem Cell TherapyOpen Access

Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma

View Full Paper

Ask AI

Bookmark

Authors

PAPınar Ataca AtillaSylvester Comprehensive Cancer Center EAErden AtillaFred Hutch Cancer Center SBSinem Civriz BozdağKoç University

Discussion

Member takes

Implication

Retrospective study reveals favorable survival with chemoimmunotherapy and stem cell transplantation in primary central nervous system lymphoma, suggesting a promising therapeutic approach.

Key Points

To review clinical characteristics and evaluate outcomes of intensive immunochemotherapy followed by stem cell transplantation in patients with primary central nervous system lymphoma.
Retrospectively analyzed the clinical features and management of 13 patients diagnosed with primary central nervous system lymphoma between 2006 and 2015.
Assessed protocols involving rituximab, methotrexate, and cytosine arabinoside (or procarbazine) followed by autologous stem cell transplantation, as well as methotrexate with radiotherapy.
All nine patients completing chemoimmunotherapy and autologous stem cell transplantation remained in complete remission, with a median overall survival of 28 ± 16 months in this group.
Treatment was associated with substantial adverse events, including febrile neutropenia in 12 patients (92%), grade 3–4 hematological toxicity in 11 patients (85%), and grade 3–4 mucositis in 11 patients (85%).
Three fatal outcomes occurred: two patients died following methotrexate and 36–45 Gy radiotherapy, and one patient with a renal transplant died following disease progression.

Cite This Study

Atilla et al. (2017) studied this question.

synapsesocial.com/papers/6aab65ca4ae153d21326ea7d https://doi.org/10.1016/j.hemonc.2017.05.030

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reveals favorable survival with chemoimmunotherapy and stem cell transplantation in primary central nervous system lymphoma, suggesting a promising therapeutic approach.

Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider